David R. Epstein is chairman of Rubius Therapeutics and executive partner at Flagship Pioneering. Most recently he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG, from 2010 to mid-2016. Previously, Mr. Epstein started up and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership, the oncology business grew to number two in the world. He has more than 25 years of extensive drug development, deal making, commercialization and people leadership experience on a global scale. Over the course of his career he led the development and commercialization of over 30 new molecular entities including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. David was recently named by FierceBiotech to be among “The 25 most influential in biopharma.” Mr. Epstein holds a B.S. degree in pharmacy with high honors from Rutgers University College of Pharmacy and an M.B.A. in finance and marketing from the Columbia University Graduate School of Business.

David R. Epstein is chairman of Rubius Therapeutics and executive partner at Flagship Pioneering. Most recently he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG, from 2010 to mid-2016. Previously, Mr. Epstein started up and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership, the oncology business grew to number two in the world. He has more than 25 years of extensive drug development, deal making, commercialization and people leadership experience on a global scale. Over the course of his career he led the development and commercialization of over 30 new molecular entities including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. David was recently named by FierceBiotech to be among “The 25 most influential in biopharma.” Mr. Epstein holds a B.S. degree in pharmacy with high honors from Rutgers University College of Pharmacy and an M.B.A. in finance and marketing from the Columbia University Graduate School of Business.